Skip to content

Clinical observation of patients with simple obesity and non-alcoholic fatty liver disease using acupoint thread embedding technique under individualized health intervention

Clinical observation of patients with simple obesity and non-alcoholic fatty liver disease using acupoint thread embedding technique under individualized health intervention

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000775
Enrollment
Unknown
Registered
2024-12-08
Start date
2024-10-08
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Simple obesity, non-alcoholic fatty liver disease

Interventions

Observation group:Individualized health intervention combined with acupoint thread embedding therapy
Control group:Individualized health interventions

Sponsors

PLA Naval Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) The actual body weight > 20% of the standard body weight; 2)BMI=28kg/m2; (3) The percentage of fat >30%; (4) The imaging findings of the liver met the diagnostic criteria for diffuse fatty liver and there was no other reason to explain it; (5) Exclude related diseases that can lead to fatty liver due to viral hepatitis, autoimmune liver disease, drug-induced liver injury, hereditary liver disease, etc.; (6) No previous alcohol history or milliliter equivalent ethanol content <140g/week (<70g/week for women); (7) Those who meet 2 of the first 3 of the above 6 items and meet the last 3 items at the same time can be diagnosed; (8) Age 18~60 years old; (9) Voluntarily participate in this trial and sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Secondary obesity; (2) other methods of treatment for obese patients within 3 months; (3) Those who use other treatments or terminate treatment on their own; (4) Patients with obvious liver injury, serum aminotransferases > 2 times the upper limit of normal, and severe liver and kidney insufficiency; (5) Pregnant or lactating women; (6) Protein allergy; (7) Other conditions that the physician deems inappropriate for treatment; (8) Patients with cardiovascular and cerebrovascular diseases, mental abnormalities, blood diseases, tumors, and diabetes.

Design outcomes

Primary

MeasureTime frame
BMI(body mass index);Waist circumference;Waist-to-hip ratio;

Secondary

MeasureTime frame
blood lipids;TCM Symptom Points;PBF;Scores before and after liver ultrasound;TCM constitution assessment;Insulin resistance index;

Countries

China

Contacts

Public ContactGuo Lin Gan

PLA Naval Medical Center

gglsh91@126.com18621825637

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026